SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reports that Nvidias board may oust Jensen Huang amid allegations involving workplace relationships and a suspected Chinese intelligence operative have driven attention to CEO succession and governance risk. Traders are divided between fearing leadership disruption and further scrutiny, and viewing the selloff as overdone because Nvidias business and chip demand remain intact; the allegations and Huangs future remain uncertain.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Traders linked AMDs sharp rally to rotation from Nvidia amid reports of leadership and governance uncertainty around Jensen Huang, with some viewing AMD as a potential beneficiary. Others argued the scandal does not change chip competitiveness or fundamentals and questioned whether the rapid move was sustainable.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is rallying on a read-through from CoreWeaves strong results and outlook, which eased concerns about demand for AI-cloud providers ahead of Nebiuss Q3 report. Traders are debating whether the sector momentum can continue, with attention on Nebiuss capacity expansion and funding needs and some warning that high expectations could set up a sell-the-news reaction.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves stronger-than-expected quarterly results and raised outlook fueled a sharp rebound in AI infrastructure stocks. Traders remain divided over its debt-heavy expansion and a reported Nvidia leadership shake-up: bears see financing and partnership risks, while bulls argue demand and the Nvidia relationship extend beyond one executive.

GraniteShares ETF Trust - GraniteShares 2x Long NVDA Daily ETF

GraniteShares 2x Long NVDA Daily ETF

Dip-buying in NVDL is prominent amid Nvidias share-price swings, while traders also circulate unverified claims about CEO Jensen Huang and an alleged insider or spy scandal. The reaction is divided: some see a buying opportunity, while others expect more downside and warn that the ETFs 2x daily leverage can magnify losses.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras upcoming earnings and the final IPO lockup expiration are driving discussion, with traders debating whether results and guidance can reverse the steep post-IPO decline or whether newly eligible shares and a repeat of the prior earnings selloff could add pressure. Bulls are positioning for a rebound or short squeeze, while bears remain wary of insider selling and execution risks.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Supermicros H15 servers powered by AMDs latest EPYC processors are now shipping, drawing attention to its AI and data-center hardware business and its reach beyond Nvidia. Traders welcomed the launch and recent rebound, while others questioned whether server demand can translate into stronger margins and cash flow amid the stocks volatility.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondass Q3 earnings report is the main focus, with traders debating whether revenue growth and guidance can offset concerns about losses, cash burn, and dilution. The recent Digital Bat drone order adds to the growth discussion, while high reported short interest fuels speculation about a squeeze; others warn that earnings could trigger another selloff.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Nvidia CEO Jensen Huang-related scrutiny is driving speculation that investors may rotate toward Broadcom and other chipmakers; traders describe AVGOs strength as benefiting from Nvidias weakness, though some doubt the move will hold and warn that both companies remain exposed to AI spending trends.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor shares rallied after management reaffirmed confidence in deramiocel and discussed possible labeling ahead of the FDAs November 22 decision on the Duchenne muscular dystrophy therapy. Traders are positioning for approval and speculating about short covering, while others stress that the outcome remains uncertain given the FDA advisory committees earlier concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced initial clinical results from the Phase 1 study of JANX011 in healthy volunteers and outlined its planned clinical development strategy...

Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Beats Revenue Estimates

Janux Therapeutics (JANX) delivered earnings and revenue surprises of +24.44% and +34.12%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended September 30, 2026, and provided a business update. During the third quarter, we continued to...

Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers

Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biopharmaceutical company developing next-generation immunotherapies, today announced that it will host a virtual event on Monday, November 9, 2026, at 8:30 a.m. ET.David Campbell, Ph.D., President and Chief Executive Officer, will present...

Ensign Group (ENSG) Beats Q3 Earnings Estimates

Ensign Group (ENSG) delivered earnings and revenue surprises of +4.64% and -0.71%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?

Iovance Biotherapeutics (IOVA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux 

Prostate cancer awareness spotlights Pfizer's Xtandi, Novartis' Pluvicto and clinical-stage programs from Candel and Janux.

4 Prostate Cancer Drug Stocks to Watch During Awareness Month

Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology company developing tumor-activated immunotherapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating JANX013, Janux's novel PSMA-targeted tumor-activated CD28 co-stimulatory...

JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know

Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.

Janux Therapeutics Inc

JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>While durable responses were observed in select patients through extended follow-up, the overall magnitude and consistency of activity were not sufficient to support continued development relative to other pipeline programs, it said.&nbsp;</li><li>However, the experimental therapy demonstrated a differentiated tolerability profile with fewer gastrointestinal, dermatologic, and subcutaneous adverse events as compared to other drugs belonging to its category.&nbsp;</li><li>The company also clarified that the decision to discontinue JANX008 is program-specific and part of its efforts to prioritize parts of its portfolio.</li></ul>Shares of Janux Therapeutics, Inc. (JANX) edged up 1% after hours after the company said on Monday that it will discontinue development of its experimental program called JANX008 to focus its resources on its remaining pipeline.The company said that it came to the decision after completing early-stage trials across multiple solid tumor indications and an internal review of the data. While durable responses were observed in select patients through extended follow-up, the overall magnitude and consistency of activity were not sufficient to support continued development relative to other pipeline programs, it said.However, the experimental therapy demonstrated a differentiated tolerability profile with fewer gastrointestinal, dermatologic, and subcutaneous adverse events as compared to other drugs belonging to its category, the company said. Overall safety profile also allows for outpatient dosing, the company noted.The company also clarified that the decision to discontinue JANX008 is program-specific and part of its efforts to prioritize parts of its portfolio.“Our decision to discontinue JANX008 reflects the disciplined approach we take to advancing our pipeline,” said David Campbell, Ph.D., President and Chief Executive Officer of Janux. “We evaluate each program against a high bar for safety, activity, and differentiated profile. We prioritize resources toward programs that meet these criteria and offer opportunities to deliver best-in-class outcomes.”Janux is currently also evaluating other experimental drugs for the treatment of prostate cancer as well as autoimmune diseases. Earlier this month, the company said that it dosed the first participant in an early-stage study of JANX014, one of its candidates for prostate cancer.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around JANX fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.JANX stock has fallen 53% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/crmd-stock-jumps-as-antifungal-drug-clears-key-trial-for-2-billion-preventive-market/cZBNx6bRePY">CRMD Stock Jumps As Antifungal Drug Clears Key Trial For $2B Preventive Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Janux Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

The company said that it came to the decision after completing early-stage trials across multiple solid tumor indications and an internal review of the data.

Vanguard Total Stock Market ETF

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$JANX dumbest 27% decline in the history of Wall Street. MMs stole retail shares. Be back to 17/18 in a week or two.

MarketWarfare

$JANX Investors may be questioning how reliably Janx can get deep B-cell depletion at a dose that patients can tolerate. Five people at the highest dose is a small sample, and the study measured B-cell depletion in healthy volunteers. Whether that translates into meaningful improvement in autoimmune disease is still open, with the first patient study targeted for the first half of 2027.

mike white

$JANX Totally flabbergasted why this went down 26% on an excellent data. Lost like 260-million-dollar market cap to near 52 week low. for what?  What was market expecting? Drug approval? 
 
And this not even their main drug which is JANX007.

$JANX lowest price since Feb 2024. Trading at 220M below cash value. Unacceptable. 

An activist needs to get in here ASAP and remove the cancer that is the CEO, David Campbell. You are out of time, you inept turd.

$JANX i dont think that remotely justifies this selloff. no major adverse events, very manageable cytokine release, most patients had remarkable B-cell depletion. the madness of this sell of is just price manipulation.

Naser A

$JANX must be in minority - was impressed with janx011 data and think there is massive potential there. Adding

bananya

$JANX we all are. good news? this stock tanks. bad news? this stock tanks. only invest in this if you like lighting money on fire.

$JANX Janux Therapeutics Inc. (JANX) has approximately $15.54 per share in cash minus debt (net cash per share). 
This metric is calculated from their latest financial data as follows: 
• Total Cash & Cash Equivalents: $970.91 million 
• Total Debt: $20.99 million 
• Net Cash Position: $949.92 million 
• Shares Outstanding: ~61.14 million

The Bob😕

$JANX company is simply incapable of releasing data without the stock price tanking. It's mind boggling.

Feed

News

Sentiment

Earnings

Fundamentals

Info

JANX Janux Therapeutics Inc

Fundamentals

Latest JANX News